— Published Date: 5/14/2025
Value Proposition: Novel antisense oligonucleotide (ASO) directly targeting a microRNA-mediated mechanism responsible for autophagy reduction and neurodegeneration in Huntington’s disease (HD) improving patient outcomes in pre-HD subjects.
Technology Description
R…
— Published Date: 5/15/2025
Value proposition: Novel analgesic compounds that block CaV3.2 currents in nociceptive dorsal root ganglion neurons in order preemptively treat pain in subjects, unlike other products that are continuously administered post onset of pain.
Technology Description
Resear…
— Published Date: 5/14/2025
Value proposition: Novel ASOs that increase key protein production to limit neurodegeneration caused by ALS and frontotemporal dementia (FTD).
Technology Description
TDP-43 pathology is present in ~97% of ALS, ~50% of FTD, and frequently observed in other neurodegenerat…
— Value Proposition: Human microbe strains with robust colonization efficacy and potent in vivo harvesting of beneficial metabolites involved in infant health.
Technology Description
Researchers from the laboratory of Dr. Jeffrey Gordon at Washington University in St. Louis have discovered str…
— Technology Description
Researchers at Washington University in St. Louis have developed a drug combination that can be used to prevent tissue injury resulting from placement of a variety of medical devices including, but not limited to, endotracheal tubes (ETTs) and catheters (bladder catheters). P…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
